arrow
D

Daisuke Tomizawa

national center for child health and development
H指数:39
被引数:5,857

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiomics analysis focusing on genome-wide DNA methylation in paediatric acute promyelocytic leukaemia

多组学分析聚焦于儿科急性早幼粒细胞白血病全基因组DNA甲基化

2026-08-210
PRE
Landscape of paediatric oncology clinical trials in Asia

亚洲儿科肿瘤学临床试验概览

2025-11-040
OAAI
Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

儿童急性髓系白血病(AML)的诊断与管理:国际专家小组的共识建议

Blood
IF23.1
2025-10-220
PRE
H3K27me3 and HOXA9 expression predict prognosis in pediatric acute myeloid leukemia: an epigenetic-transcriptional correlation study

H3K27me3和HOXA9表达预测儿童急性髓系白血病的预后:一项表观遗传-转录相关性研究

2025-09-250
OAAI
Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study

三氧化二砷在强化治疗新诊断儿童急性早幼粒细胞白血病中的安全性与有效性:JPLSG AML-P13研究的结果

2025-09-010
PRE
Real-world Outcomes of Commercial Tisagenlecleucel for Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia in Japan

商业Tisagenlecleucel治疗日本儿童、青少年和年轻成人急性淋巴细胞白血病的真实世界结果

2025-02-011
OAAI
A Retrospective Study of Pediatric Patients With Low- or Intermediate-Risk Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation for the AML-05 Study Conducted by the Japanese Pediatric Leukemia/ Lymphoma Study Group
2024-11-010
PRE
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

儿童 γ δ t-all的生物学和临床分析将LMO2/STAG2重排确定为极高风险

2024-06-242
PRE
A higher CD34+cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia
2024-04-290
OAAI
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia
LEUKEMIA
IF13.4
2024-04-181
PRE
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia
LEUKEMIA
IF13.4
2023-11-062
OA